A new report gives low marks to the United States in the health of its citizens, finding that Americans have higher rates of injury and disease and die sooner than their counterparts in other developed countries.

Drug maker Shire has started a research program focused on rare diseases and their effects on patients and healthcare professionals, the company said Monday.

If you're a student of pharmacy today, this is what you have to look forward to in the retail pharmacy setting: working with local, state and national health departments on creating market-driven disease state management programs; actually practicing what your professors have been preaching over the past six years; applying patient management skills over prescription adjudication skills; and making a real difference in your patients' lives.

Retail pharmacies have been offering testing for diseases ranging from high cholesterol to cancer for years, but offering HIV testing presents a whole new realm of possibilities and challenges.

An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

Medication nonadherence costs the U.S. healthcare system about $290 billion per year, according to New England Healthcare Institute. That big and scary number — the kind whose sheer enormity can make one’s eyes glaze over — is now even bigger.


The first study to report the effects vitamin D has on the immune system of people with lupus was unveiled Saturday at the American College of Rheumatology Annual Scientific Meeting in Chicago.

Specialty pharmacy services company Armada Health Care has enlisted a New York pharmacy professor to assist in the review of developed clinical protocols and medication assessment tools, Armada said Monday.

Researchers from the University of Texas Health Science Center at Houston found that patients with diabetes are at higher risk of contracting tuberculosis, a deadly bacterial disease, than nondiabetics.

More than 400 drugs are in late-stage clinical development or awaiting Food and Drug Administration approval as treatments for rare diseases, according to a report by the drug industry lobby.